Kiniksa Pharmaceuticals (KNSA) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Kiniksa Pharmaceuticals Revenue Highlights


Latest Revenue (Y)

$270.26M

Latest Revenue (Q)

$112.21M

Main Segment (Y)

Product

Kiniksa Pharmaceuticals Revenue by Period


Kiniksa Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$270.26M22.74%
2022-12-31$220.18M471.24%
2021-12-31$38.54M100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31--

Kiniksa Pharmaceuticals generated $270.26M in revenue during NA 2023, up 22.74% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Kiniksa Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-09-30$112.21M3.30%
2024-06-30$108.63M36.03%
2024-03-31$79.86M-4.24%
2023-12-31$83.39M24.38%
2023-09-30$67.05M-6.19%
2023-06-30$71.47M47.84%
2023-03-31$48.34M-21.88%
2022-12-31$61.88M-37.58%
2022-09-30$99.14M267.55%
2022-06-30$26.97M-16.21%
2022-03-31$32.19M71.72%
2021-12-31$18.75M54.98%
2021-09-30$12.10M57.00%
2021-06-30$7.70M100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31--

Kiniksa Pharmaceuticals generated $112.21M in revenue during Q3 2024, up 3.30% compared to the previous quarter, and up 157.00% compared to the same period a year ago.

Kiniksa Pharmaceuticals Revenue Breakdown


Kiniksa Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22
Product$233.18M$122.52M
Collaboration$37.08M$97.66M

Kiniksa Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (86.28%), and Collaboration (13.72%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22
Collaboration$6.21M$5.24M$14.42M$16.98M$5.69M$21.95M---
Product$112.21M$103.39M$136.02M$54.49M$42.66M$39.94M$33.42M$26.97M$22.19M

Kiniksa Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (94.76%), and Collaboration (5.24%).

Kiniksa Pharmaceuticals Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
KNSAKiniksa Pharmaceuticals$270.26M$112.21M
CHRSCoherus BioSciences$257.24M$64.98M
ACLXArcellx$110.32M$27.38M
SPROSpero Therapeutics$96.73M$10.20M
BOLTBolt Biotherapeutics$7.88M$1.27M
KRONKronos Bio$6.29M$2.69M
LYRALyra Therapeutics$1.56M$598.00K
PHATPhathom Pharmaceuticals$682.00K$1.91M
KRTXKaruna Therapeutics$654.00K-
CGEMCullinan Oncology--
GPCRStructure Therapeutics--
GRCLGracell Bio--
NUVLNuvalent--
COGTCogent Biosciences--
GOSSGossamer Bio-$95.84M
DAWNDay One Biopharmaceuticals-$20.07M
CERECerevel Therapeutics--
REPLReplimune Group--
KURAKura Oncology--
NLTXNeurogene--
VTYXVentyx Biosciences--
LRMRLarimar Therapeutics--
NVCTNuvectis Pharma--

KNSA Revenue FAQ


Kiniksa Pharmaceuticals's yearly revenue for 2023 was $270.26M, representing an increase of 22.74% compared to 2022. The company's yearly revenue for 2022 was $220.18M, representing an increase of 471.24% compared to 2021. KNSA's yearly revenue for 2021 was $38.54M, representing an increase of 100.00% compared to 2020.

Kiniksa Pharmaceuticals's quarterly revenue for Q3 2024 was $112.21M, a 3.30% increase from the previous quarter (Q2 2024), and a 67.37% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $108.63M, a 36.03% increase from the previous quarter (Q1 2024), and a 51.99% increase year-over-year (Q2 2023). KNSA's quarterly revenue for Q1 2024 was $79.86M, a -4.24% decrease from the previous quarter (Q4 2023), and a 65.18% increase year-over-year (Q1 2023).

Kiniksa Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 601.17%, and for the last 5 years (2019-2023) was 0%.

Kiniksa Pharmaceuticals's revenue streams in c 23 are Product, and Collaboration. Product generated $233.18M in revenue, accounting 86.28% of the company's total revenue, up 90.31% year-over-year. Collaboration generated $37.08M in revenue, accounting 13.72% of the company's total revenue, down -62.03% year-over-year.

For the fiscal year ending Dec 23, the largest source of revenue of Kiniksa Pharmaceuticals was Product. This segment made a revenue of $233.18M, representing 86.28% of the company's total revenue.